Bristol Myers Squibb (BMY) is currently trading at a 51% discount to the sector median, presenting a strong buy opportunity due to its compelling risk/reward profile. The company achieved 15% year-over-year revenue growth driven by its growth portfolio, which offsets challenges from the decline of Opdivo and the upcoming patent expiry of Eliquis. BMY offers a 3.7% forward dividend yield, strong profit margins, and accelerating earnings growth, making it attractive for defensive and income-focused investors. Despite some concerns over its capital structure and market skepticism, there is potential upside if BMY continues to grow revenue and successfully executes its research and development plans.
Alexandria Real Estate Equities, a leading life science real estate company, marked Blood Cancer Awareness Month by spotlighting its investments and tenants developing treatments for blood cancers like leukemia and lymphoma. The company emphasized it...
Bristol Myers Squibb (BMY) is considered undervalued, trading at a forward P/E of 9.8x with a 3.7% dividend yield. Its growth portfolio now accounts for nearly 60% of revenue, helping offset declines in legacy drugs and supporting 5% year-over-year r...
RBC Capital Markets reaffirmed its 'outperform' rating on Oxford BioMedica, despite clinical trial pauses by partners Novartis and BMS. The broker views the trial halts as having limited financial impact, with only £10-16 million in annual clinical r...
The Health Care Select Sector SPDR Fund (XLV) offers broad healthcare exposure but delivers a low dividend yield around 1.5% due to its cap-weighted structure favoring large, lower-yield stocks like Eli Lilly. Directly owning top XLV holdings AbbVie,...
